早期的皮尔芬尼治疗可以提高异常性肺纤维化患者的肺功能
1Medical School, University of Exeter, Exeter EX4 4PS, United Kingdom. j.zhang5@exeter.ac.uk.
World journal of clinical cases
|October 7, 2024
概括
对异常性肺纤维化 (IPF) 的早期皮尔芬尼治疗显著减缓了疾病的进展,并保持了肺功能. 这项研究强调了在IPF早期启动皮尔芬尼的好处,以改善患者的治疗结果.
科学领域:
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
- 放射学 放射学是一门学科.
背景情况:
- 异形性肺纤维化 (IPF) 是一种进展性肺病,治疗选择有限.
- 皮尔芬尼已被批准用于IPF,但其在早期疾病中的有效性需要进一步调查.
- 早期干预可以在管理IPF进展方面提供显著的好处.
研究的目的:
- 评估早期皮尔芬尼治疗对异常性肺纤维化 (IPF) 患者肺功能的疗效.
- 定义IPF的早期和高级阶段,并强调pirfenidone在每一个阶段的好处.
- 强调综合诊断方法的重要性,包括成像和生物化学数据,以评估治疗的有效性.
主要方法:
- 对接受早期皮尔芬尼治疗的IPF患者的回顾性分析.
- 评估肺功能参数 (例如,强迫生命能力).
- 计算机断层扫描 (CT) 影像的利用与生化标志物和肺功能测试一起.
主要成果:
- 早期的皮尔芬尼干预显著降低了IPF患者疾病进展的速度.
- 在早期接受皮尔芬尼治疗的患者中观察到肺功能的保存.
- 这项研究支持使用皮尔芬尼作为早期IPF的关键治疗策略.
结论:
- 在IPF的早期阶段开始皮尔芬尼治疗是一种可行的策略,可以减缓疾病的进展.
- 包括CT成像在内的全面的患者评估对于评估皮尔芬尼的疗效至关重要.
- 早期治疗皮尔芬尼具有显著的潜力,可以改善IPF患者的长期结果.
相关概念视频
01:25Pulmonary Function Tests
311
Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
311
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
155
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
155
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
132
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
132
01:28Pulmonary Tuberculosis V
170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170
01:20COPD: Pathogenesis and Clinical Features
242
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
242
01:28Pneumonia IV: Management
305
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
305